Foundry Healthcare CompEquIss Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.11T | 51.11% |
2ABBV | ABBVIE INC | Healthcare | $449.63B | 20.69% |
3MCK | MCKESSON CORP | Healthcare | $101.14B | 4.66% |
4COR | CENCORA INC | Healthcare | $59.91B | 2.76% |
5CAH | CARDINAL HEALTH INC | Healthcare | $53.52B | 2.46% |
6RVMD | REVOLUTION MEDICINES INC | Healthcare | $39.58B | 1.82% |
7TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $37.30B | 1.72% |
8MRNA | MODERNA INC | Healthcare | $24.53B | 1.13% |
9INSM | INSMED INC | Healthcare | $23.48B | 1.08% |
10UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 1.05% |
11THC | TENET HEALTHCARE CORP | Healthcare | $16.79B | 0.77% |
12MEDP | MEDPACE HOLDINGS INC | Healthcare | $15.36B | 0.71% |
13DVA | DAVITA INC | Healthcare | $15.21B | 0.70% |
14EXEL | EXELIXIS INC | Healthcare | $14.06B | 0.65% |
15MDGL | MADRIGAL PHARMACEUTICALS INC | Healthcare | $12.76B | 0.59% |
16ALGN | ALIGN TECHNOLOGY INC | Healthcare | $12.66B | 0.58% |
17AXSM | AXSOME THERAPEUTICS INC | Healthcare | $11.84B | 0.54% |
18KRYS | KRYSTAL BIOTECH INC | Healthcare | $10.46B | 0.48% |
19NUVL | NUVALENT INC | Healthcare | $9.79B | 0.45% |
20CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 0.45% |
21CRNX | CRINETICS PHARMACEUTICALS INC | Healthcare | $8.84B | 0.41% |
22IMVT | IMMUNOVANT INC | Healthcare | $8.27B | 0.38% |
23RYTM | RHYTHM PHARMACEUTICALS INC | Healthcare | $7.31B | 0.34% |
24MIRM | MIRUM PHARMACEUTICALS INC | Healthcare | $7.25B | 0.33% |
25LQDA | LIQUIDIA CORP | Healthcare | $7.11B | 0.33% |
26LNTH | LANTHEUS HOLDINGS INC | Healthcare | $7.00B | 0.32% |
27COGT | COGENT BIOSCIENCES INC | Healthcare | $6.68B | 0.31% |
28AMRX | AMNEAL PHARMACEUTICALS INC | Healthcare | $5.69B | 0.26% |
29TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 0.24% |
30KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $4.92B | 0.23% |
31VKTX | VIKING THERAPEUTICS INC | Healthcare | $4.31B | 0.20% |
32CPRX | CATALYST PHARMACEUTICALS INC | Healthcare | $3.85B | 0.18% |
33NHC | NATIONAL HEALTHCARE CORP | Healthcare | $3.56B | 0.16% |
34XRAY | DENTSPLY SIRONA INC | Healthcare | $2.81B | 0.13% |
35TRVI | TREVI THERAPEUTICS INC | Healthcare | $2.71B | 0.12% |
36AGL | AGILON HEALTH INC | Healthcare | $2.17B | 0.10% |
37ADMA | ADMA BIOLOGICS INC | Healthcare | $2.02B | 0.09% |
38UFPT | UFP TECHNOLOGIES INC | Healthcare | $1.87B | 0.09% |
39MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $1.87B | 0.09% |
40NVCR | NOVOCURE LTD | Healthcare | $1.84B | 0.08% |
41HROW | HARROW INC | Healthcare | $1.74B | 0.08% |
42TDOC | TELADOC HEALTH INC | Healthcare | $1.70B | 0.08% |
43ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.08% |
44NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.59B | 0.07% |
45PRGO | PERRIGO CO PLC | Healthcare | $1.48B | 0.07% |
46NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.06% |
47CRVS | CORVUS PHARMACEUTICALS INC | Healthcare | $1.25B | 0.06% |
48IRMD | IRADIMED CORP | Healthcare | $1.24B | 0.06% |
49AZTA | AZENTA INC | Healthcare | $1.21B | 0.06% |
50QDEL | QUIDELORTHO CORP | Healthcare | $1.19B | 0.05% |
51TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.17B | 0.05% |
52ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.16B | 0.05% |
53SVRA | SAVARA INC | Healthcare | $1.13B | 0.05% |
54CAPR | CAPRICOR THERAPEUTICS INC | Healthcare | $1.13B | 0.05% |
55MNPR | MONOPAR THERAPEUTICS | Healthcare | $744M | 0.03% |
56PHR | PHREESIA INC | Healthcare | $662M | 0.03% |
57FLGT | FULGENT GENETICS INC | Healthcare | $573M | 0.03% |
58CTEV | CLARITEV CORP | Healthcare | $518M | 0.02% |
59ARVN | ARVINAS INC | Healthcare | $517M | 0.02% |
60PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.02% |
61EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $394M | 0.02% |
62ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.02% |
63ELMD | ELECTROMED INC | Healthcare | $349M | 0.02% |
64LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $311M | 0.01% |
65SGHT | SIGHT SCIENCES INC | Healthcare | $274M | 0.01% |
66SPOK | SPOK HOLDINGS INC | Healthcare | $222M | 0.01% |
67SENS | SENSEONICS HOLDINGS INC | Healthcare | $214M | 0.01% |
68AGEN | AGENUS INC | Healthcare | $209M | 0.01% |
69AMWL | AMERICAN WELL CORP | Healthcare | $199M | 0.01% |
70INGN | INOGEN INC | Healthcare | $178M | 0.01% |
71ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.01% |
72LENZ | LENZ THERAPEUTICS INC | Healthcare | $162M | 0.01% |
73OWLT | OWLET INC | Healthcare | $162M | 0.01% |
74JYNT | JOINT CORP | Healthcare | $127M | 0.01% |
75OPRX | OPTIMIZERX CORP | Healthcare | $126M | 0.01% |
76RLYB | RALLYBIO CORP | Healthcare | $87M | 0.00% |
77ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.00% |
78CLNN | CLENE INC | Healthcare | $76M | 0.00% |
79LONA | LEONABIO INC | Healthcare | $68M | 0.00% |
80IMA | IMAGENEBIO INC | Healthcare | $61M | 0.00% |
81MCRB | SERES THERAPEUTICS INC | Healthcare | $52M | 0.00% |
82TIL | INSTIL BIO INC | Healthcare | $50M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $2.17T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 87% toward Growth. +1% unclassified (13 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 2003 → July 2026; the right-hand end is the same value as the box’s dot. 82 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual38.2%Margin-36.8%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual51.1%Margin-26.1%Days required to liquidate the largest position at 20% of one day's dollar volume.
Required<= 7.0 daysActualunboundedMargin—
At least 50% of total assets must sit in cash, government securities, other RICs, and other securities limited to 5% of assets and 10% of the issuer's voting securities per issuer.
Required>= 50.0%Actual38.2%Margin-11.8%Arithmetically entailed by '40 Act 5(b)(1) diversification (75%/5% asset leg) — it cannot fail independently, so it is reported outside the tally rather than counted as a separate check.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 82 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 271 monthly observations · about 2.7 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 19%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (21 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 33.9% | -36.2% |
| 3 yearsp.a. | 16.2% | -10.6% |
| 5 yearsp.a. | 6.9% | -2.5% |
| 10 yearsp.a. | 11.0% | 3.3% |
| Since inceptionp.a. | 11.3% | 6.1% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 6.0% | -21.7% |
| 2025 | 24.0% | -24.0% |
| 2024 | 10.5% | 17.6% |
| 2023 | 10.3% | -7.0% |
| 2022 | -15.8% | 24.8% |
| 2021 | 13.3% | 29.0% |
| 2020 | 28.3% | 0.2% |
| 2019 | 17.5% | -11.0% |
| 2018 | 8.5% | 21.9% |
| 2017 | 23.4% | 28.7% |
| 2016 | -13.5% | 18.1% |
| 2015 | 10.5% | 19.0% |
| 2014 | 26.5% | -16.4% |
| 2013 | 51.6% | 7.0% |
| 2012 | 17.8% | 0.2% |
| 2011 | 14.9% | 17.6% |
| 2010 | 10.3% | 1.3% |
| 2009 | 17.4% | -5.1% |
| 2008 | -30.4% | -2.3% |
| 2007 | 6.3% | 9.0% |
| 2006 | -1.3% | -5.1% |
| 2005 | 30.2% | 26.4% |
| 2004 | 18.1% | 42.9% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare CompEquIss Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a CompEquIss signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.